Abstract
Introduction
Plasmodium falciparum is the most lethal malarial parasite, which attacks more than 500 million people and kills 2 million of them each year, mainly children aged less than 5 in Africa [1] . Control measures against this threatening disease are therefore desperately needed, such as development of vaccine and new anti-malarial drugs. [3] .
It has to be kept in mind when developing a totally effective vaccine against P. falciparum malaria that as suggested by transcriptome analysis, around 58-90 merozoite proteins are involved in this parasite's invasion of red blood cell (RBC) [2] and a similar number of sporozoite proteins could be acting in hepatocyte invasion
Molecular Immunology Most merozoite-recognized proteins have been functionally and molecularly studied by others [4] as well as by ourselves [5] .
Work by other groups has shown that their synthesis and expression can be switched on and off [6] (depending on parasite invasion requirements and/or immunological pressure [7] ) and trimmed [8] or processed [9] to perform their biological functions.
A totally effective anti-malarial vaccine must therefore contain at least a similar number of merozoite and sporozoite proteins or epitopes representing these molecules' most relevant functional parts (multi-epitope, multi-stage) to ensure complete blocking of the parasite during its critical invasion stages [5, 10] .
The first multi-epitope, multi-stage, subunit-based, anti-malarial vaccine, named SPf66, was developed by us 20 years ago [11, 12] following a large set of experiments in Aotus monkeys involving synthetic peptides. It showed that chemically synthesized vaccines were feasible, safe and immunogenic, providing complete protection for ~40% of immunized monkeys and humans exposed to experimental challenge [11, 12] . It was ~38.8% in humans in Colombia [13] , 55 .1% in Venezuela [14] , 60 .8% in Ecuador [15] , 31% in Tanzania [16] for up to 2 years [17] in large field trials carried out on individuals aged more than 1 year [13, 16] [40] , or may be weakly bound to the merozoite surface or associated with other membrane proteins like MSP-3, -6 and -7 [41] [42] [43] which are bound to MSP-1 [44] forming large macromolecular complexes [9] or lipid rafts during invasion (Fig. 2) [51, 52] (Fig. 1) . [53, 54] , serve as support for others that are loosely bound (MSP-6, -7, Pf41) for mediating coordinated interaction with RBCs (Fig. 2) .
in different ethnic and epidemiological set-ups around the world. SPf66 was ineffective in infants aged less than 1 [18] and a batch with a different degree of polymerization produced elsewhere was not protective [19], thereby dropping its protective efficacy in a recent meta-analysis [20]. SPf66 contained four epitopes; three of them were merozoitederived, chemically synthesized, high-activity binding peptides (HABPs) attaching to RBC [21], and one a circumsporozoite protein-derived, having high hepatocyte-binding ability [12]. SPf66 taught us that a protection-inducing immune response should thus be directed against the parasite's functionally relevant amino acid sequences (i.e. HABPs), specifically conserved ones (to rule out the P. falciparum parasite's tremendous genetic polymorphism). SPf66 also taught us the importance of the host's genetic variability linked to major histocompatibility (MHC)-peptide-T-cell receptor (TCR) complex formation, since non-responders and non-protected individuals typing HLA-DR␤1*04 [22] preferentially used TCR V␤3 and V␤11 families [23]. This experimental, clinical and field trial data clearly suggested that genetic control of HLA-DR␤1* allele-associated immune response had to be very seriously taken into account when developing vaccines. Here we briefly show that this approach is completely feasible. Besides the parasite's genetic polymorphism, the human immune system's genetic polymorphism associated with controlling the immune response and dominated by major histocompatibility complex class II molecules (MHC II
)
Most of these proteins organize themselves into detergentresistant membrane (DRM)-associated macromolecular complexes where some of them, anchored to the membrane via GPI tails (MSP-1, -2, -4, -5 and RAMA)
These molecules allow the junction to be formed and merozoite interaction with erythrocytes before the cellular complex becomes irreversibly bound. Many more proteins have been involved in merozoite invasion of RBC [44] but only the most relevant in this are mentioned. [56] [57] [58] .
Erythrocyte proteins involved in merozoite invasion

Merozoite invasion of erythrocytes is mediated by molecular communication between both types of cell. Merozoites must "persuade" erythrocytes to help in forming the PV membrane so that successful invasion can occur. Taking the erythrocyte cytoskeleton apart or destabilizing it occurs so that the intracellular vacuole can be formed; it thus becomes one of the main biochemical events occurring during invasion. The merozoite must send the information from outside the erythrocyte, penetrating the erythrocyte membrane via the transmembrane proteins that interact with the RBC cytoskeleton, such as sialoglycoproteins (i.e. glycophorin A, B and C) [55] and band 3. It has been reported that glycophorins A and B interact with merozoite protein erythrocyte-binding antigen 175 (EBA-175), glycophorin C with EBA-140 protein and band 3 with a merozoite surface protein 1 fragment (MSP-1) called MSP-142 and acid basic repeat antigen (ABRA) protein (MSP-9). Evidence has also been presented that glycophorins mediate initially weak, relatively nonspecific merozoite binding to RBC, where net glycophorin load is very important
Enzyme treatment of different RBCs has been described, as have binding assays involving different antigens and receptor X. P. falciparum normocyte binding protein 1 (PfNBP1) binds to erythrocytes, such adhesion being dependent on a neuraminidasesensitive, trypsin-resistant Z receptor. P. falciparum reticulocyte homologue 2b protein (PfRH2b) ligand mediates invasion through a chymotrypsin-sensitive, trypsin/neuraminidase-resistant recep-
tor, which has also been referred to as receptor Z [59] .
The state of current worldwide anti-malarial vaccine approaches
More than 40 assays in humans summarized by Engers and Godal by 1998 [60] [62] [63] [64] . [70, 71] . This can be defined by: [70] [71] [72] . Figure 3 shows the amino acid sequences of EBA-175 [71] , MSP-2 [73] , AMA-1 [74] and histidine-rich protein II (HRP-II) [75] Fig. 2A) [74] (Fig. 4) [92, 93] . 
Fig. 2 Macromolecular complexes of merozoite proteins involved in RBC invasion present on detergent-resistant membrane (DRM), DRM-associated lipid rafts as recognized in DRM proteomes. Molecule sizes are drawn at their approximate molecular weights. Some molecules remain anchored to the parasites' DRM-associated lipid rafts via their GPI tails (shown as black twists traversing the pale blue membrane) such as MSP-1 (golden), MSP-2 (light blue), MSP-4 (pink), MSP-5 (dark blue), Pf 92 (brown), Pf 12 (clear purple) and RAMA (purple). Some other molecules are non-covalently bound, like RAP-1, -2 and -3 molecules to RAMA and MSP-6 (fuchsia) and -7 (green) to MSP-1. All members of the high (Rhop H) molecular weight rhoptry proteins having transmembrane sequences were also identified in proteome analysis. Another raft is formed by MSP-1 82-kD, 30-kD, 38-kD fragments (gold) and MSP-1 33-kD (red) and the 19-kD (red) fragment anchored to the merozoite membrane via the GPI tail to which some other molecules bind non-covalently, as shown in the central portion of this figure. (A) front and (B) top
R (receptor) + L (ligand) = RL in equilibrium (r -b) (l -b) b K = (b)/(r -b)(l -b)( 1 )
Structural analysis of native and modified HABPs
When searching for an association between immunological activity and native and modified HABP structure as determined by 1 H-NMR analysis it was noticed that the changes made induced striking structural modifications in these peptides (numbered according our Institute's code where bold is used throughout the rest of this article to distinguish modified HABPs from native ones shown in brackets). ␣-helixes were thus shortened in 24292 peptides derived from (1815), 23230 (6746), 13446 (1522) and 22812 (1779), ␣-helixes were displaced in 13450 (1585) and 20034 (4325), short ␣-helixes were induced in random-configuration peptides in 14044 (4337) and ␤-turn tendency modified as in 13492 (6671). Distorting classical-type III ␤-turns were induced as in 24112 (4044) or in 24166 (1818) (random structure that could not be classified by CD). All such modifications rendered these peptides immunogenic and protection-inducing against experimental challenge (Table 3). It was suggested that modifying these HABPs probably led to a better fit into HLA-DR␤1* molecules; their ability to bind to these MHC-II molecules was therefore analysed (
Fig. 4 An example of competition binding assays with 4313, 4325 and 4337 conserved HABP analogues (AMA-1 derived) [74]. Original radioisotope-labelled peptide-specific binding inhibited by analogous peptide is shown at 100 and 800 nM. The inhibition assay was performed with original non-labelled peptides and their analogous peptides. The asterisk (*) represents original peptides' specific binding.
Underlined residues corresponding to the critical binding residues, whose modifications were analysed at 10, 100 and 800 nM concentrations (only two are shown in the figure), displayed the same reduced RBC binding pattern (у50%) when modified. 
These tailored HABPs displayed binding motifs and reading registers specific for those alleles to which they bound [24, 94]. Peptides 13450, 24292 and 23230 thus bound to HLA-DR␤1*0301 having residues Y, I and W (respectively) fitting into this molecule's Pocket 1; D, D and A fitted into Pocket 4; A, E and K fitted into Pocket 6 and Y, L and L fitted into Pocket
Secondary structure analysis
Native and modified HABP secondary structure circular dichroism (CD) analysis of 100 conserved malarial HABPs [95] identified in the 25 most relevant P. falciparum merozoite proteins involved in RBC invasion (Fig. 5) (Fig. 5) .
The Dictionary of Protein Secondary Structure (DPSS) [100] has identified three helix types (310 or G, ␣ or H, π or I), turns (represented by T), strands (E), bridges (B), bends (S) and other secondary structures (L). Identifying such structures in conserved HABPs by an easy and accessible methodology such as CD analysis will lead to the easier design of immunogenic and protection-inducing peptides.
Native and modified HABP 3D structure explains some immunological phenomena (Fig. 6C) .
H NMR analysis has also revealed that orientation varied in
modified HABP residues according to the haplotypes to which they bound (Fig. 6A and B Fig. 6A and B) . Similar behaviour could be observed ( Fig. 6A and B (Fig. 7E) , whilst modified HABP residues bound to HLA-DR_1*0101 (from haplotype DR1) in P3 (aquamarine), P5 (pink) and P8 (yellow) ( Fig. 6A  and B; Table 3 ). Identical results have been found for many other peptides [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] [91] .
Supporting the haplotype-and allele-conscious TCR concept
The above findings were supported by X-ray crystallography studies of HLA-DR␤1*0401 molecule binding haemagglutinin (HA) [24, 94] . This strongly supports our findings concerning the existence of some other pockets [102] .
Modified HABPs' 3D structure revealed a fit into HLA molecules
The docking and molecular modelling of modified HABP 24112 (immunogenic and protection-inducing) into the HLA-DR␤1*0401 molecule (code 2SEB in PDB) [103] (Fig. 7A and B [103] . Figure 7D shows Varied crossing angle geometry in the MHC-Class II-peptide-TCR complexes, ranging from 40° to 87°, from diagonal [104] to near orthogonal [105] and some additional lateral mobility along the groove [106] 
